BofA Downgrades Leidos Holdings Amidst Healthcare Challenges

Investment bank BofA downgraded Leidos Holdings to neutral from buy with a price target of $125. Leidos Holdings' healthcare performance is a concern, affecting the company's upside in the defense sector.

BofA Securities downgraded Leidos Holdings to neutral from buy. The investment bank assigned a price target of $125. This action comes as healthcare headwinds impact the company's performance.

Leidos Holdings operates in the defense sector, where healthcare challenges pose a significant risk. Investors are reevaluating the company's prospects as a result.

This development could be an opportunity to reassess the stock's valuation. Analysts believe Leidos Holdings might be 38% undervalued. However, more information is needed to confirm this analysis.

BofA's downgrade is the latest in a series of concerns affecting Leidos Holdings' stock. The company's shares are experiencing a downturn due to these challenges.